Journal article
Antiviral candidates for treating hepatitis E virus infection
NE Netzler, DE Tuipulotu, SG Vasudevan, JM Mackenzie, PA White
Antimicrobial Agents and Chemotherapy | AMER SOC MICROBIOLOGY | Published : 2019
DOI: 10.1128/AAC.00003-19
Abstract
Globally, hepatitis E virus (HEV) causes significant morbidity and mortality each year. Despite this burden, there are no specific antivirals available to treat HEV patients, and the only licensed vaccine is not available outside China. Ribavirin and alpha interferon are used to treat chronic HEV infections; however, severe side effects and treatment failure are commonly reported. Therefore, this study aimed to identify potential antivirals for further development to combat HEV infection. We selected 16 compounds from the nucleoside and nonnucleoside antiviral classes that range in developmental status from late preclinical to FDA approved and evaluated them as potential antivirals for HEV i..
View full abstractRelated Projects (2)
Grants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
We thank Suzanne Emerson (National Institute of Allergy and Infectious Diseases, NIH) and X. J. Meng (Virginia-Maryland College of Veterinary Medicine) for generously providing the plasmid to generate the G1 HEV replicon used in this study. We also thank Mark Douglas (Westmead Institute for Medical Research, Sydney, Australia) for providing the Huh7 cell line used in this study. We thank Kitti Wing-Ki Chan (Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore) for her assistance during our collaboration. Finally, we thank Gerhard Purstinger (formerly of Institute of Pharmacy, University of Innsbruck, Austria) for providing the compound GPC-N114. This work was funded by the National Health and Medical Research Council, grant/award numbers APP1083139 and APP1123135. N.E.N. and P.A.W. conceived the study, D.E.T. assisted N.E.N. with experimental design, and N.E.N. designed and performed the experiments under the supervision of P.A.W. S.G.V. and J.M.M. provided expertise and materials. N.E.N. and P.A.W. analyzed and interpreted the data. N.E.N. wrote the manuscript with the help of P.A.W., and it was edited by D.E.T., S.G.V., and J.M.M. We have no conflicts of interest to declare and nothing to disclose.